

- 26 -

### CLAIMS

1. Use of a CC-chemokine mutant having a reduced GAG-binding activity for the treatment of liver fibrotic inflammatory and/or autoimmune diseases, wherein the CC-chemokine is CCL3 / MIP-1alpha, CCL4 / MIP-1beta, or CCL5 / RANTES.
2. The use of claim 1 wherein the CC-chemokine is CCL5/ RANTES and the mutant is triple 40's RANTES mutant (SEQ ID NO: 1).
3. The use of claim 1 wherein the CC-chemokine is CCL3 / MIP-1alpha and the mutant is triple MIP-1alpha mutant (SEQ ID NO: 2).
4. The use of claim 1 wherein the CC-chemokine is CCL4 / MIP-1beta and the mutant is triple MIP-1beta mutant (SEQ ID NO: 3).
5. The use of any of the claims from 1 to 4 wherein the CC-chemokine mutant is an active variant of said CC-chemokine mutant in which one or more amino acids have been inserted, deleted, or substituted in a conservative manner.
6. The use of any of the claims from 1 to 5 wherein the CC-chemokine mutant is comprised in a polypeptide additionally comprising an amino acid sequence belonging to a protein sequence other than the corresponding CC-chemokine.
7. The use of any of the claims from 1 to 6 wherein the CC-chemokine mutant is in the form of an active precursor, salt, derivative, conjugate or complex.

- 27 -

8. Use of a CC-chemokine mutant having reduced GAG-binding activity in the preparation of a pharmaceutical composition for liver fibrotic inflammatory and/or autoimmune diseases, wherein the CC-chemokine is CCL3 / MIP-1alpha, CCL4 / MIP-1beta, or CCL5 / RANTES.
9. The use of any of the preceding claims wherein the liver disease is an alcoholic liver disease, a viral hepatitis, or an autoimmune hepatitis
10. Methods for the treatment or prevention of liver fibrotic inflammatory and/or autoimmune diseases, comprising the administration of an effective amount of a CC-chemokine mutant having reduced GAG-binding activity, wherein the CC-chemokine is CCL3 / MIP-1alpha, CCL4 / MIP-1beta, or CCL5 / RANTES.